Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

Inclusion Criteria:

Histological proof of prostatic adenocarcinoma via a minimum of 6 core biopsy samples
Clinical stage T1c or T2 with high-grade disease (Gleason's 8-10) on initial biopsy, or clinical stage T2b-T2c with Gleason's grade >/= 7 and PSA > 10ng/ml.
No evidence of metastatic disease as determined by CT scans and bone scans.
Eastern Cooperative Oncology Group (ECOG) Performance Status of Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (ANC) > 1,500 and platelet count of > 100,000.
Normal pituitary and adrenal function
Patients should be deemed to be candidates for radical prostatectomy.

Exclusion Criteria:

Histological variants in the primary tumor (histological variants other than adenocarcinoma); neuroendocrine tumor
Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
Uncontrolled hypertension
Abnormal Liver function
Active or symptomatic viral hepatitis or chronic liver disease
Clinically significant heart disease
Other active malignancy
History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
Previous treatment with abiraterone acetate
Patients who are not appropriate surgical candidates for radical prostatectomy
Prior chemotherapy or radiation therapy for prostate cancer.
Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study

Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.